HRP20180506T1 - Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela - Google Patents
Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela Download PDFInfo
- Publication number
- HRP20180506T1 HRP20180506T1 HRP20180506TT HRP20180506T HRP20180506T1 HR P20180506 T1 HRP20180506 T1 HR P20180506T1 HR P20180506T T HRP20180506T T HR P20180506TT HR P20180506 T HRP20180506 T HR P20180506T HR P20180506 T1 HRP20180506 T1 HR P20180506T1
- Authority
- HR
- Croatia
- Prior art keywords
- locus
- meganuclease
- human
- artificial
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 16
- 230000009261 transgenic effect Effects 0.000 title claims abstract 15
- 108090000623 proteins and genes Proteins 0.000 title claims 6
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims abstract 8
- 210000004027 cell Anatomy 0.000 claims 7
- 210000004602 germ cell Anatomy 0.000 claims 7
- 210000001161 mammalian embryo Anatomy 0.000 claims 7
- 210000000287 oocyte Anatomy 0.000 claims 6
- 230000010354 integration Effects 0.000 claims 4
- 230000006801 homologous recombination Effects 0.000 claims 2
- 238000002744 homologous recombination Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 101150097493 D gene Proteins 0.000 claims 1
- 230000007018 DNA scission Effects 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims 1
- 101150008942 J gene Proteins 0.000 claims 1
- 241001504654 Mustela nivalis Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 101150117115 V gene Proteins 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 210000002257 embryonic structure Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000001360 synchronised effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8775—Murine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
Claims (16)
1. Postupak za ciljanu integraciju umjetnog imunoglobulinskog (Ig) mjesta u primateljskoj ne-humanoj zametnoj stanici, oplođenoj jajnoj stanici ili embrijima, koji obuhvaća: uvođenje u ne-ljudsku zametnu stanicu primatelja, gnojivo jajne stanice ili embrij mjesto specifične meganukleaze usmjerene na endogeni Ig lokus i transgenski vektor koji sadrži umjetni Ig lokus tako da umjetni Ig lokus integrira u genom primateljske ne-humane zametne stanice, oplođene oocite ili embrije ciljanom integracijom i zamjenjuje endogeni Ig lokus ili njihove dijelove homolognim rekombinacijom; gdje meganukleaza povećavaju učestalost homologne rekombinacije kroz dvostruko DNA cijepanje.
2. Postupak sukladno patentnom zahtjevu 1, naznačena time, da je meganukleaza osigurana u konstruktu ekspresije koju je moguće regulirati.
3. Postupak sukladno patentnom zahtjevu 2, naznačena time, da je meganukleaza operativno povezana s inducibilnim promotorom.
4. Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, što se nadalje sastoji od odabira stanice u kojoj je umjetni Ig lokus integriran na ciljano mjesto i u kojem su regulativni konstrukti ekspresije meganukleaze integrirani u genom.
5. Postupak sukladno patentnom zahtjevu 4, naznačena time, da nadalje uključuje spajanje odabrane stanice sa stanicom za nuklearnu prijenosnu jedinicu koja nije ljudska, totipotentna i sposobna za tvorbu funkcionalnog novorođenog tkiva, kako bi se dobila rezultirajuća stanica.
6. Postupak sukladno patentnom zahtjevu 4 ili 5, naznačena time, da je enukleizirana stanična jedinica nuklearnog prijenosa oocit ili embrionalna matična stanica.
7. Postupak sukladno bilo kojem od patentnih zahtjeva 4 do 6, naznačen time, da nadalje sadrži:
I. Injektirane odabrane stanice u razvoj ne-ljudskog embrija; ili
II. kultiviranje rezultirajuće stanice u odgovarajućem mediju i prenošenje u nastalu stanicu u sinkronizirani primatelj za generiranje transgenične ne-humane životinje.
8. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da umjetni Ig lokus sadrži fragmente ljudskih i ne-humanih Ig-lokusa.
9. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da umjetni Ig lokus sadrži najmanje jedan segment humanog V gena.
10. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da umjetni Ig lokus obuhvaća više segmenata imunoglobulinskog gena, pri čemu segmenti gena sadrže najmanje jedan segment genske regije V, jedan ili više segmenata J, jedan ili više segmenata gena D i jednu ili više konstanta regijskih gena.
11. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da ciljana sekvenca meganukleaze je prisutna u ili proksimalno za segmente gena odabranih od: J segment gena; i genski segment konstantne regije.
12. Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, naznačen time, da sukladno bilo kojem prethodnom patentnom zahtjevu, nadalje obuhvaća uporabu druge meganukleaze, pri čemu druga meganukleaza prepoznaje drugu ciljnu sekvencu meganukleaze prisutnu u ili proksimalnom endogenom Ig lokusu i selektivno cijepa endogeni Ig lokus zajedno s prvom meganukazom, ali na mjestu različitom od prve meganukleaze, čime se inaktivira najmanje jedan endogeni Ig lokus
13. Transgenska ne-humana životinja, koja se može dobiti metodom sukladno zahtjevu 9, naznačena time, da životinja sadrži:
I. najmanje jedan regulirabilni konstrukt genomskog meganukleaza ekspresije; i
II. umjetni Ig lokus koji zamjenjuje endogeni Ig lokus;
pri čemu je životinja sposobna proizvesti protutijelo koje ima ljudski idiotip.
14. Transgenska životinja sukladno patentnog zahtjevu 13, naznačena time, da je ta životinja odabrana između ptice, glodara, i lasice.
15. Transgenska životinja sukladno patentnom zahtjevu 14, naznačeno time, da je ta životinja štakor.
16. In vitro primjena transgenskog vektora za ciljanu integraciju,
pri čemu transgeni vektor sadrži induskcijsku ekspresijsku kontrolnu regiju koju je moguće
koja je operabilno povezana s nukleinskom kiselinom koja kodira mjesno specifičnu meganukleazu koja cilja endogeni Ig lokus, pri čemu uporaba obuhvaća:
uvođenje transgeničnog vektora u primateljsku ne-ljudsku zametnu stanicu, oplođene oocite ili embrij tako da se transgenski vektor integrira u genom zametne stanice, oplođene oocite ili embrija; i uvođenje transgenskog vektora koji sadrži umjetni Ig lokus u primateljsku ne-humanu zametnu stanicu, oplođeno oocite ili embrij, tako da se umjetni lokus integrira u genom primateljske ne-humane zametne stanice, oplođene oocite ili embrija ciljanom integracijom
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94161907P | 2007-06-01 | 2007-06-01 | |
US4432408P | 2008-04-11 | 2008-04-11 | |
EP12187787.2A EP2602323B1 (en) | 2007-06-01 | 2008-05-30 | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20180506T1 true HRP20180506T1 (hr) | 2018-05-04 |
Family
ID=40111008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180506TT HRP20180506T1 (hr) | 2007-06-01 | 2018-03-27 | Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela |
Country Status (22)
Country | Link |
---|---|
US (6) | US8703485B2 (hr) |
EP (4) | EP3382022A1 (hr) |
JP (6) | JP5823690B2 (hr) |
KR (4) | KR101886610B1 (hr) |
CN (1) | CN101784664B (hr) |
AT (1) | ATE522611T1 (hr) |
AU (1) | AU2008259939B2 (hr) |
CA (2) | CA2688834C (hr) |
CY (1) | CY1120383T1 (hr) |
DK (3) | DK2602323T3 (hr) |
ES (3) | ES2393826T3 (hr) |
HK (1) | HK1135138A1 (hr) |
HR (1) | HRP20180506T1 (hr) |
HU (1) | HUE037302T2 (hr) |
IL (2) | IL202302A (hr) |
LT (1) | LT2602323T (hr) |
NZ (1) | NZ581396A (hr) |
PL (3) | PL2336329T3 (hr) |
PT (3) | PT2152880E (hr) |
SG (2) | SG182144A1 (hr) |
SI (1) | SI2602323T1 (hr) |
WO (1) | WO2008151081A1 (hr) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
AU2008259939B2 (en) | 2007-06-01 | 2014-03-13 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
WO2010026443A1 (en) * | 2008-09-08 | 2010-03-11 | Cellectis | Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof |
LT2346994T (lt) | 2008-09-30 | 2022-03-10 | Ablexis, Llc | Knock-in pelė, skirta chimerinių antikūnų gamybai |
EP3156494B8 (en) * | 2008-12-04 | 2018-09-19 | Sangamo Therapeutics, Inc. | Genome editing in rats using zinc-finger nucleases |
JP5827127B2 (ja) | 2008-12-18 | 2015-12-02 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用 |
GB0905023D0 (en) * | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
PT2564695E (pt) | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
ES2595376T3 (es) | 2009-12-10 | 2016-12-29 | Regeneron Pharmaceuticals, Inc. | Ratones que producen anticuerpos de cadena pesada |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
RS55315B2 (sr) | 2010-02-08 | 2020-08-31 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
LT3248462T (lt) * | 2010-03-31 | 2024-05-27 | Ablexis, Llc | Pelių genų inžinerija, skirta chimerinių antikūnų gamybai |
CN103228130B (zh) * | 2010-06-17 | 2016-03-16 | 科马布有限公司 | 动物模型及治疗分子 |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
US10881084B2 (en) | 2010-07-26 | 2021-01-05 | Trianni, Inc | Transgenic animals and methods of use |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
KR102434557B1 (ko) | 2010-08-02 | 2022-08-23 | 리제너론 파아마슈티컬스, 인크. | Vl 도메인을 포함하는 결합 단백질을 생성하는 마우스 |
US9920110B2 (en) | 2011-03-09 | 2018-03-20 | Cell Signaling Technology, Inc. | Methods and reagents for creating monoclonal antibodies |
BR112013025567B1 (pt) * | 2011-04-27 | 2021-09-21 | Amyris, Inc | Métodos para modificação genômica |
PT2739740T (pt) | 2011-08-05 | 2020-01-09 | Regeneron Pharma | Cadeia leve universal humanizada de murganhos |
JP2014533930A (ja) * | 2011-09-19 | 2014-12-18 | カイマブ・リミテッド | 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬 |
ES2961613T3 (es) | 2011-09-21 | 2024-03-12 | Sangamo Therapeutics Inc | Métodos y composiciones para la regulación de la expresión transgénica |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
US10246509B2 (en) | 2011-10-17 | 2019-04-02 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
PL2847335T3 (pl) * | 2012-04-25 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Celowanie dużymi wektorami do celowania wspomagane nukleazą |
SG10201609277PA (en) | 2012-06-12 | 2017-01-27 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
KR20150023670A (ko) * | 2012-06-12 | 2015-03-05 | 제넨테크, 인크. | 조건적 녹아웃 대립유전자의 생성 방법 및 이를 위한 조성물 |
WO2014093908A2 (en) * | 2012-12-14 | 2014-06-19 | Omt, Inc. | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
MY185881A (en) | 2013-02-20 | 2021-06-14 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
PL2967012T3 (pl) | 2013-03-14 | 2021-04-19 | Erasmus University Medical Center Rotterdam | Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał |
US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US20160040155A1 (en) * | 2013-04-16 | 2016-02-11 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
AU2014253942B9 (en) | 2013-04-16 | 2020-08-13 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
RU2725520C2 (ru) | 2013-12-11 | 2020-07-02 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
US20150266976A1 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
KR20210088756A (ko) | 2014-03-21 | 2021-07-14 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
EA038470B1 (ru) | 2014-04-30 | 2021-09-01 | Ханол Биофарма Ко., Лтд. | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ |
US10336825B2 (en) | 2014-04-30 | 2019-07-02 | Hanall Biopharma Co., Ltd. | Antibody binding to FcRn for treating autoimmune diseases |
GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
KR102374379B1 (ko) | 2014-06-06 | 2022-03-17 | 리제너론 파마슈티칼스 인코포레이티드 | 표적화된 좌를 변형시키는 방법 및 조성물 |
SG11201610633QA (en) | 2014-06-26 | 2017-01-27 | Regeneron Pharma | Methods and compositions for targeted genetic modifications and methods of use |
WO2016016442A1 (en) | 2014-08-01 | 2016-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An anti-cd45rc antibody for use as drug |
KR102531016B1 (ko) | 2014-11-21 | 2023-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물 |
CA2971213C (en) | 2014-12-19 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification through single-step multiple targeting |
JP2018508224A (ja) | 2015-03-19 | 2018-03-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗原を結合する軽鎖可変領域を選択する非ヒト動物 |
WO2016161446A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
BR112018002824A2 (pt) | 2015-08-11 | 2018-11-06 | Open Monoclonal Tech Inc | anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo |
AU2016311268B2 (en) * | 2015-08-24 | 2023-02-02 | Trianni, Inc. | Enhanced production of immunoglobulins |
WO2017095939A1 (en) | 2015-12-03 | 2017-06-08 | Trianni, Inc. | Enhanced immunoglobulin diversity |
AU2017213633B2 (en) | 2016-02-04 | 2023-08-03 | Trianni, Inc. | Enhanced production of immunoglobulins |
KR102598120B1 (ko) | 2016-06-03 | 2023-11-07 | 리제너론 파마슈티칼스 인코포레이티드 | 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물 |
PT4050034T (pt) | 2016-09-14 | 2024-05-27 | Teneoone Inc | Anticorpos de ligação a cd3 |
JP2020502991A (ja) | 2016-09-20 | 2020-01-30 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗pcsk9抗体 |
WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
IL300729A (en) | 2016-12-21 | 2023-04-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
EA201991514A1 (ru) | 2016-12-21 | 2019-12-30 | Сефалон, Инк. | Антитела, которые специфически связываются с ил-15, и их применение |
SG11201906540WA (en) | 2017-01-19 | 2019-08-27 | Open Monoclonal Tech Inc | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
WO2018237006A1 (en) | 2017-06-20 | 2018-12-27 | Teneoone, Inc. | ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS |
IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-BCMA antibodies containing only heavy chains |
MX2020002612A (es) | 2017-09-07 | 2020-07-13 | Univ Res Inst Inc Augusta | Anticuerpos de la proteina de muerte celular programada 1. |
KR20200044094A (ko) | 2017-09-13 | 2020-04-28 | 테네오바이오, 인코포레이티드 | 엑토효소에 결합하는 중쇄 항체 |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
SG11202006042SA (en) | 2017-12-27 | 2020-07-29 | Teneobio Inc | Cd3-delta/epsilon heterodimer specific antibodies |
CN116874591A (zh) | 2018-03-24 | 2023-10-13 | 瑞泽恩制药公司 | 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途 |
CA3102125A1 (en) * | 2018-06-13 | 2019-12-19 | Crystal Bioscience Inc. | Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion |
US12102070B2 (en) * | 2018-06-13 | 2024-10-01 | Crystal Bioscience Inc. | Camelization of a human variable domain by gene conversion |
SG11202012084WA (en) | 2018-06-14 | 2021-01-28 | Regeneron Pharma | Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences |
SG11202011597RA (en) | 2018-07-20 | 2020-12-30 | Teneobio Inc | Heavy chain antibodies binding to cd19 |
AU2019312576A1 (en) | 2018-08-01 | 2021-02-25 | Cephalon, LLC | Anti-CXCR2 antibodies and uses thereof |
EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
EP3914616A1 (en) | 2019-01-23 | 2021-12-01 | Encefa | Cd31 competitors and uses thereof |
CN117099741A (zh) | 2019-02-18 | 2023-11-24 | 百奥赛图(北京)医药科技股份有限公司 | 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物 |
JP2022538733A (ja) | 2019-05-20 | 2022-09-06 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) | 新規抗cd25抗体 |
MX2021015337A (es) | 2019-06-14 | 2022-01-18 | Teneobio Inc | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. |
WO2021058795A2 (en) | 2019-09-27 | 2021-04-01 | Stark Labs | Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof |
CA3163549A1 (en) | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Peptide-mhc ii protein constructs and uses thereof |
PE20230431A1 (es) | 2020-04-29 | 2023-03-08 | Teneobio Inc | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas |
CN115667532A (zh) | 2020-06-02 | 2023-01-31 | 百奥赛图(北京)医药科技股份有限公司 | 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物 |
TW202229328A (zh) | 2020-09-11 | 2022-08-01 | 美商再生元醫藥公司 | 抗原特異性抗體之鑑定及產生 |
US20240002522A1 (en) | 2020-11-20 | 2024-01-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Anti-cd25 antibodies |
JP2024504547A (ja) | 2020-11-20 | 2024-02-01 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) | 抗cd25抗体 |
KR20230147048A (ko) | 2020-12-16 | 2023-10-20 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 Fc 알파 수용체를 발현하는 마우스 |
US20240317849A1 (en) | 2020-12-23 | 2024-09-26 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
WO2023170207A1 (en) | 2022-03-09 | 2023-09-14 | Alderaan Biotechnology | Anti-cd160 transmembrane isoform antibodies |
AU2023281650A1 (en) | 2022-05-30 | 2024-10-17 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
WO2024062019A1 (en) | 2022-09-21 | 2024-03-28 | Synabs | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4977081A (en) | 1987-05-04 | 1990-12-11 | Adi Diagnostics, Inc. | Stable rabbit-mouse hybridomas and secretion products thereof |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1992001043A1 (fr) | 1990-07-10 | 1992-01-23 | Nkk Corporation | Hydridomes produisant une immunoglobuline g aviaire specifique |
US5612205A (en) | 1990-08-29 | 1997-03-18 | Genpharm International, Incorporated | Homologous recombination in mammalian cells |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE4119749A1 (de) | 1991-06-15 | 1992-12-17 | Claas Ohg | Verfahren zum entholzen von flachs und flachsaufbereitungsmaschine zur durchfuehrung dieses verfahrens |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
EP0583980A1 (en) | 1992-08-20 | 1994-02-23 | Eli Lilly And Company | Method for generating monoclonal antibodies from rabbits |
EP2192131A1 (en) | 1992-08-21 | 2010-06-02 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
US5795974A (en) | 1993-12-10 | 1998-08-18 | University Of Utah Research Foundation | Mycoplasma arthritidis superantigen |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
AU7326796A (en) | 1995-10-30 | 1997-05-22 | Spectral Diagnostics Inc. | Stable chicken b-cell line and method of use thereof |
US5716081A (en) | 1996-03-11 | 1998-02-10 | Automotive Products (Usa), Inc. | Spring clip for quick connect coupling |
CA2273194C (en) * | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
AU2391000A (en) * | 1998-12-31 | 2000-07-31 | J. David Gladstone Institutes, The | Transgenic rodents and rodent cell lines expressing hiv co-receptors |
US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
AU7676300A (en) * | 1999-10-12 | 2001-04-23 | Cambridge Antibody Technology Limited | Human anti-adipocyte monoclonal antibodies and their use |
AU5561301A (en) * | 2000-04-24 | 2001-11-20 | American Home Prod | Transgenic animal |
IL154751A0 (en) * | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
EP1916303B1 (en) * | 2000-11-30 | 2013-02-27 | Medarex, Inc. | Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
WO2003016495A2 (en) | 2001-08-20 | 2003-02-27 | Merck & Co., Inc. | Transgenic rodents as animal models for modulation of b1 bradykinin receptor protein |
ATE466088T1 (de) * | 2001-09-14 | 2010-05-15 | Cellectis | Zufällige integration von polynukleotide nach in vivo linearisierung |
ES2645698T3 (es) * | 2001-11-30 | 2017-12-07 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
CA2479153C (en) | 2002-03-15 | 2015-06-02 | Cellectis | Hybrid and single chain meganucleases and use thereof |
ATE531796T1 (de) * | 2002-03-21 | 2011-11-15 | Sangamo Biosciences Inc | Verfahren und zusammensetzungen zur verwendung von zinkfinger-endonukleasen zur verbesserung der homologen rekombination |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
JP4966006B2 (ja) * | 2003-01-28 | 2012-07-04 | セレクティス | カスタムメイドメガヌクレアーゼおよびその使用 |
WO2004072115A2 (en) * | 2003-02-05 | 2004-08-26 | Therapeutic Human Polyclonals, Inc. | Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies |
GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
RS20050934A (en) * | 2003-06-16 | 2008-04-04 | Celltech R. & D. Inc., | Antibodies specific for sclerostin and methods fo r increasing bone mineralization |
JP2007537704A (ja) * | 2003-07-15 | 2007-12-27 | セラピューティック ヒューマン ポリクローナルズ, インコーポレイテッド | ヒト化免疫グロブリン遺伝子座 |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
WO2005019463A1 (en) * | 2003-08-11 | 2005-03-03 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis with humanized immunoglobulin loci |
WO2005038001A2 (en) * | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
KR20120091471A (ko) | 2004-03-04 | 2012-08-17 | 도쿠리츠교세이호진 고쿠리츠간켄큐센터 | 래트 배아 줄기 세포 |
SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
KR20070072608A (ko) * | 2004-10-22 | 2007-07-04 | 레비비코르 인코포레이션 | 유전자 변형된 면역계를 가지는 유제류 |
CA2584814A1 (en) * | 2004-10-22 | 2006-05-04 | Therapeutic Human Polyclonals, Inc. | Suppression of endogenous immunoglobulin expression in non-human transgenic animals |
WO2006093337A1 (ja) * | 2005-03-03 | 2006-09-08 | Takeda Pharmaceutical Company Limited | 癌の予防・治療剤 |
ATE466933T1 (de) | 2005-03-15 | 2010-05-15 | Cellectis | I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung |
WO2006097784A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
US7491866B2 (en) | 2005-11-09 | 2009-02-17 | Board Of Regents University Of Texas System | Transgenic rats and spermatogonial stem cells |
KR101481843B1 (ko) | 2006-01-25 | 2015-01-12 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 형질전환 동물 내에서의 중쇄만의 항체의 생성 |
JP5514539B2 (ja) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
AU2008259939B2 (en) * | 2007-06-01 | 2014-03-13 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
MY185881A (en) * | 2013-02-20 | 2021-06-14 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
-
2008
- 2008-05-30 AU AU2008259939A patent/AU2008259939B2/en active Active
- 2008-05-30 ES ES11161775T patent/ES2393826T3/es active Active
- 2008-05-30 ES ES12187787.2T patent/ES2664218T3/es active Active
- 2008-05-30 PL PL11161775T patent/PL2336329T3/pl unknown
- 2008-05-30 EP EP18158882.3A patent/EP3382022A1/en active Pending
- 2008-05-30 DK DK12187787.2T patent/DK2602323T3/en active
- 2008-05-30 CN CN2008801012988A patent/CN101784664B/zh active Active
- 2008-05-30 DK DK11161775.9T patent/DK2336329T3/da active
- 2008-05-30 WO PCT/US2008/065419 patent/WO2008151081A1/en active Application Filing
- 2008-05-30 PT PT08769934T patent/PT2152880E/pt unknown
- 2008-05-30 PL PL12187787T patent/PL2602323T3/pl unknown
- 2008-05-30 US US12/130,818 patent/US8703485B2/en active Active
- 2008-05-30 SG SG2012039913A patent/SG182144A1/en unknown
- 2008-05-30 KR KR1020177002729A patent/KR101886610B1/ko active IP Right Grant
- 2008-05-30 EP EP11161775A patent/EP2336329B8/en active Active
- 2008-05-30 CA CA2688834A patent/CA2688834C/en active Active
- 2008-05-30 KR KR1020187022408A patent/KR102096731B1/ko active IP Right Grant
- 2008-05-30 EP EP08769934A patent/EP2152880B1/en active Active
- 2008-05-30 HU HUE12187787A patent/HUE037302T2/hu unknown
- 2008-05-30 JP JP2010510537A patent/JP5823690B2/ja active Active
- 2008-05-30 EP EP12187787.2A patent/EP2602323B1/en active Active
- 2008-05-30 PL PL08769934T patent/PL2152880T3/pl unknown
- 2008-05-30 ES ES08769934T patent/ES2372718T3/es active Active
- 2008-05-30 KR KR1020097024974A patent/KR101661357B1/ko active IP Right Grant
- 2008-05-30 KR KR1020157022196A patent/KR101703299B1/ko not_active Application Discontinuation
- 2008-05-30 AT AT08769934T patent/ATE522611T1/de active
- 2008-05-30 DK DK08769934.4T patent/DK2152880T3/da active
- 2008-05-30 SG SG10201509853UA patent/SG10201509853UA/en unknown
- 2008-05-30 SI SI200831937T patent/SI2602323T1/en unknown
- 2008-05-30 PT PT111617759T patent/PT2336329E/pt unknown
- 2008-05-30 LT LTEP12187787.2T patent/LT2602323T/lt unknown
- 2008-05-30 CA CA3054224A patent/CA3054224A1/en active Pending
- 2008-05-30 PT PT121877872T patent/PT2602323T/pt unknown
- 2008-05-30 NZ NZ581396A patent/NZ581396A/en unknown
-
2009
- 2009-11-24 IL IL202302A patent/IL202302A/en active IP Right Grant
-
2010
- 2010-02-05 US US12/701,464 patent/US8907157B2/en active Active
- 2010-03-18 HK HK10102837.1A patent/HK1135138A1/xx unknown
-
2011
- 2011-07-27 US US13/192,407 patent/US9388233B2/en active Active
-
2012
- 2012-06-06 IL IL220209A patent/IL220209A/en active IP Right Grant
-
2013
- 2013-10-11 JP JP2013213996A patent/JP2014027947A/ja active Pending
-
2015
- 2015-07-30 JP JP2015150597A patent/JP6220827B2/ja active Active
-
2016
- 2016-07-08 US US15/206,063 patent/US10072069B2/en active Active
-
2017
- 2017-09-29 JP JP2017190442A patent/JP6712254B2/ja active Active
-
2018
- 2018-03-27 CY CY20181100345T patent/CY1120383T1/el unknown
- 2018-03-27 HR HRP20180506TT patent/HRP20180506T1/hr unknown
- 2018-09-10 US US16/127,065 patent/US20190169270A1/en not_active Abandoned
-
2020
- 2020-05-27 JP JP2020092210A patent/JP2020125360A/ja active Pending
- 2020-12-22 US US17/131,164 patent/US20210253673A1/en active Pending
-
2022
- 2022-06-23 JP JP2022101081A patent/JP2022118217A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180506T1 (hr) | Pripravci i postupci za inhibiranje endogenih imunoglobinskih gena i proizvodnju transgenskih humanih idiotipnih protutijela | |
Kuroiwa et al. | Cloned transchromosomic calves producing human immunoglobulin | |
Dyck et al. | Making recombinant proteins in animals–different systems, different applications | |
Cooper et al. | Innovative approaches to genome editing in avian species | |
ES2827482T3 (es) | Uso de un ratón para producir anticuerpos híbridos que contienen regiones variables humanas y regiones constantes de ratón como fuente de ADN que codifica una región variable humana de dicho anticuerpo | |
BR112014026294B1 (pt) | Método para modificar um lócus genômico alvo em uma célula tronco embrionária (es) de camundongo | |
CN111471719A (zh) | 有效的非减数分裂等位基因渐渗 | |
KR20200093570A (ko) | 조작된 면역글로불린 람다 경쇄를 갖는 비-인간 동물 및 그의 용도 | |
Tizard et al. | Potential benefits of gene editing for the future of poultry farming | |
CN105658050A (zh) | 用于制备具有可分选精子的动物的遗传技术 | |
CN109112159A (zh) | 基于Cas9介导的定点整合FABP4基因和MSTN基因点突变打靶载体及重组细胞 | |
Jones | Bicentennial: Genetic engineering of a mouse: Dr. Frank Ruddle and somatic cell genetics | |
CA2501415A1 (en) | Method of selecting cells for somatic cell nuclear transfer | |
CA2300972A1 (en) | Use of mariner transposan in the production of transgenic animals | |
Zou et al. | Dominant expression of a 1.3 Mb human Igk locus replacing mouse light chain production | |
JP7426120B2 (ja) | ノックイン細胞の作製方法 | |
KR20210106412A (ko) | 유전적으로 변형된 불임 조류 및 이의 재구성 방법 | |
CN106978416A (zh) | 一种基因定位整合表达系统及其应用 | |
US20190045761A1 (en) | Inducible disease models methods of making them and use in tissue complementation | |
Duncan et al. | Chromosomal engineering | |
Cyriac et al. | Transgenic chicken: methods and applications. | |
CN114606270B (zh) | 一种Mia3条件性基因敲除小鼠模型的构建方法 | |
Guo et al. | Multiplexed genome engineering for porcine fetal fibroblasts with gRNA–tRNA arrays based on CRISPR/Cas9 | |
KR101724805B1 (ko) | 유전자 적중 물질을 이용한 조류 유전자 편집방법 및 유전자 편집 조류 | |
US20240090480A1 (en) | Split-intein methods and compositions for generation of single sex offspring |